Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
They will check your skin type and suggest the best option for you
Key Points Peyronie's disease is a disorder of the penis occurring in men over 40 years of age, and is clinically associated with penile pain in the flaccid or erect state, penile deviation, penile plaques, and erectile dysfunction The aim of medical therapy is to treat and alleviate the morbidity associated with this disease The etiology is poorly understood, and this might account for the questionable efficacy of some current medical therapies Several mechanisms have been postulated as the cause in susceptible individuals, including trauma, collagen deposition, aberrant wound healing, and fibrosis Agents that have been shown in well-designed, randomized, placebo-controlled trials to have an effect in Peyronie's disease include intralesional verapamil, colchicine, and possibly intralesional interferon This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access 189,00 per year only 15,75 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
Its ability to scavenge reactive oxygen species (ROS) is especially critical given the CNSs high metabolic activity and inherent susceptibility to oxidative stress-induced cellular injury
BPC-157 takes effect at different rates, depending on tissue type, injury severity, and administration consistency
It has a molecular weight of 848.81 g/mol and the formula C 35 H 48 N 10 O 15 (CAS 62568-57-4)
